A phase II study of interferon-α2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma
MZ Schultz, AC Buzaid, WJ Poo - Melanoma research, 1997 - journals.lww.com
A phase II trial was conducted to determine the efficacy and toxicity of the addition of
interferon-[alpha] 2b (IFN-a [alpha]) to the chemotherapy combination of dacarbazine
(DTIC), carmustine (BCNU), cisplatin and tamoxifen (DBCT), in patients with stage III or IV
melanoma. Treatment consisted of DTIC 220 mg/m2 and cisplatin 25 mg/m2 intravenously
on days 1-3, BCNU 100 mg/m2 IV on day 1 only, tamoxifen 20 mg orally twice daily and IFN-
[alpha] 5 x 106 units/m2 subcutaneously on days 1-5. Cycles were repeated every 4 weeks …
interferon-[alpha] 2b (IFN-a [alpha]) to the chemotherapy combination of dacarbazine
(DTIC), carmustine (BCNU), cisplatin and tamoxifen (DBCT), in patients with stage III or IV
melanoma. Treatment consisted of DTIC 220 mg/m2 and cisplatin 25 mg/m2 intravenously
on days 1-3, BCNU 100 mg/m2 IV on day 1 only, tamoxifen 20 mg orally twice daily and IFN-
[alpha] 5 x 106 units/m2 subcutaneously on days 1-5. Cycles were repeated every 4 weeks …
以上显示的是最相近的搜索结果。 查看全部搜索结果